Cyclophosphamide: Clinical Uses, Dosing, Monitoring, and Safety
Primary Clinical Indications
Cyclophosphamide is indicated for malignancies, systemic autoimmune rheumatic diseases with interstitial lung disease (SARD-ILD), ANCA-associated vasculitis, lupus nephritis, pemphigus vulgaris, and minimal change nephrotic syndrome in children. 1, 2, 3, 4
Malignant Diseases
- Breast cancer regimens utilize cyclophosphamide at 500-600 mg/m² IV every 14-21 days as part of combination chemotherapy (AC, TAC, TC regimens) 2
- Oral dosing for malignancies ranges from 1-5 mg/kg/day for both initial and maintenance therapy 4
- Treatment duration and cumulative dose depend on tumor response and toxicity profile 4
ANCA-Associated Vasculitis (AAV)
Rituximab is now conditionally recommended over cyclophosphamide for remission induction in active, severe GPA/MPA due to lower long-term toxicity, though cyclophosphamide remains an effective alternative. 5, 6
- Intravenous pulsed dosing: 500-750 mg/m² every 4 weeks for 6 months (maximum 1500 mg per dose) 1, 7, 6
- Oral continuous dosing: 2 mg/kg/day (maximum 200 mg/day) for 3-6 months 1, 7, 8
- IV pulse therapy results in lower cumulative doses and reduced long-term toxicity compared to oral administration, though may carry slightly higher relapse risk 7, 6
- Treatment should be limited to 3-6 months maximum to minimize toxicity 7, 8
Lupus Nephritis (Class III/IV)
- Initial therapy combines corticosteroids with either cyclophosphamide or mycophenolate mofetil 3
- NIH regimen: Intravenous cyclophosphamide with monthly monitoring 3
- Euro-Lupus regimen: Lower cumulative doses (500 mg IV every 2 weeks for 6 doses) 3
- Intravenous dosing is preferable over oral due to lower cumulative exposure and simplified monitoring 3
SARD-Associated Interstitial Lung Disease
- Intravenous: 500-750 mg/m² every 4 weeks for 6 months 1
- Oral: Starting at 50-150 mg/day, target 2 mg/kg/day (maximum 200 mg/day) for 6 months 1
- Reserved for severe or progressive disease despite first-line therapy 1
Pemphigus Vulgaris
- Dexamethasone-cyclophosphamide-pulse (DCP) regimen: 500 mg IV monthly combined with 50 mg/day oral cyclophosphamide in multi-phase protocols lasting 12+ months 9, 8
- Alternative dosing: 15 mg/kg IV monthly without daily oral cyclophosphamide 9
- Reserved for severe or recalcitrant cases due to long-term toxicity concerns 9
Minimal Change Nephrotic Syndrome (Pediatric)
- Dosing: 2 mg/kg/day orally for 8-12 weeks (maximum cumulative dose 168 mg/kg) 4
- Critical limitation: Treatment beyond 90 days significantly increases sterility risk in males 4
Dosing Schedules and Administration
Route-Specific Considerations
Intravenous administration is preferred when feasible due to lower cumulative doses, reduced bladder toxicity risk, and less frequent monitoring requirements compared to oral therapy. 3, 6
- IV pulse: Requires administration every 2-4 weeks with CBC monitoring 10-14 days post-dose 1
- Oral continuous: Requires weekly CBC monitoring initially, then every 4 weeks on stable dosing 1
Timing and Hydration
Cyclophosphamide must be taken in the morning with aggressive hydration to minimize hemorrhagic cystitis risk. 4
- Adequate fluid intake or infusion should be administered during or immediately after dosing to force diuresis 4
- Capsules must be swallowed whole—never opened, chewed, or crushed 4
Bladder Protection
Mesna (2-mercaptoethanesulfonate) should be co-administered with intravenous cyclophosphamide to reduce hemorrhagic cystitis risk. 9, 7
- Mesna binds toxic acrolein metabolites in urine 7
- With IV cyclophosphamide: oral or IV mesna administered concurrently 9, 7
- With oral cyclophosphamide: mesna benefit is present but administration is more complex 7
Monitoring Parameters
Hematologic Monitoring
Complete blood count with differential is the cornerstone of cyclophosphamide monitoring due to dose-limiting myelosuppression. 1, 10
Intravenous Dosing
- Baseline CBC with differential 1
- CBC 10-14 days after each administration 1
- CBC immediately before next scheduled dose 1
Oral Dosing
- Baseline CBC with differential 1
- CBC 10-14 days after starting therapy 1
- CBC 10-14 days after any dose increase 1
- CBC every 4 weeks once on stable dosing 1
Urinary Monitoring
Urinalysis is essential for detecting hemorrhagic cystitis, which occurs in approximately 6% of patients. 9
- Baseline urinalysis 1
- Urinalysis every 4-8 weeks during treatment (IV or oral) 1
- Annual urine cytology indefinitely after any cyclophosphamide exposure due to bladder cancer risk 1
- Patients should report pink or red urine immediately 4
Additional Monitoring
- Temperature monitoring with immediate reporting of fever due to infection risk 4, 10
- Cardiac monitoring for new dyspnea, edema, palpitations, or rapid weight gain 4
- Respiratory symptom surveillance for non-infectious pneumonitis 4
Major Toxicities and Safety Considerations
Myelosuppression and Infection Risk
Neutropenia is the dose-limiting toxicity, with nadir typically occurring 7-21 days post-administration. 1, 10
- Grade 3-4 neutropenia occurs in 37-56% of patients depending on regimen 2
- Dose reduction or discontinuation required for acute or progressive leukopenia 7
Pneumocystis jirovecii prophylaxis is strongly recommended for all patients receiving cyclophosphamide, particularly when combined with corticosteroids. 7, 10
- Trimethoprim-sulfamethoxazole 800/160 mg on alternate days or 400/80 mg daily (preferred) 7
- Continue until prednisone-equivalent dose ≤5 mg/day 10
- Pentamidine alternative if trimethoprim-sulfamethoxazole contraindicated 7
Hemorrhagic Cystitis and Bladder Cancer
- Hemorrhagic cystitis occurs in approximately 6% of patients 9
- Long-term bladder cancer risk necessitates annual urine cytology after any cyclophosphamide exposure 1
- Risk increases with cumulative dose and duration of therapy 5
Fertility and Reproductive Toxicity
Cyclophosphamide causes significant gonadotoxicity with dose- and duration-dependent infertility risk. 4
- Females: 20-85% develop amenorrhea; risk of premature menopause 9, 4
- Males: Azoospermia common; treatment beyond 90 days significantly increases sterility risk 9, 4
- Fertility preservation: Leuprolide for women receiving IV cyclophosphamide; sperm banking for men 3
Contraception requirements:
- Females: Effective contraception during treatment and for 1 year after completion 4
- Males: Effective contraception during treatment and for 4 months after completion 4
Embryo-Fetal Toxicity
- Pregnancy category D: Risk of fetal harm and pregnancy loss 4
- Females must inform providers of known or suspected pregnancy immediately 4
- Lactation: Discontinue breastfeeding during treatment and for 1 week after last dose 4
Malignancy Risk
- Long-term risk of secondary malignancies, including bladder cancer and hematologic malignancies 5
- Risk increases with cumulative dose and repeated courses 5
Other Significant Toxicities
- Cardiotoxicity: Monitor for heart failure symptoms; avoid concurrent anthracyclines 2, 4
- Pulmonary toxicity: Non-infectious pneumonitis possible 4
- Gastrointestinal: Nausea, vomiting, stomatitis common 4
- Pituitary-adrenal suppression: Occurs in up to 55% of patients on prolonged therapy 9
Critical Safety Protocols
Handling Precautions
Cyclophosphamide is a cytotoxic agent requiring strict handling protocols. 4
- Caregivers must wear gloves when handling containers and capsules 4
- Avoid exposure to broken capsules 4
- If contact with broken capsules occurs, wash hands immediately and thoroughly 4
Drug Discontinuation
- Discontinue during active infection episodes 10
- Dose modification required for neutropenia or other severe adverse events 4
Common Pitfalls to Avoid
- Inadequate hydration: Always ensure forced diuresis to prevent bladder toxicity 4
- Omitting mesna: Co-administer with IV cyclophosphamide to reduce hemorrhagic cystitis 9, 7
- Insufficient monitoring: Adhere strictly to CBC and urinalysis schedules 1
- Ignoring fertility concerns: Discuss preservation options before treatment initiation 3, 4
- Prolonged duration: Limit treatment to recommended timeframes (3-6 months for AAV, <90 days for pediatric nephrotic syndrome) to minimize toxicity 7, 8, 4
- Forgetting long-term surveillance: Annual urine cytology required indefinitely after any cyclophosphamide exposure 1